Abstract
Renal cell carcinomas (RCCs) occur in both sporadic and familial forms. In a subset of families the occurrence of RCCs co-segregates with the presence of constitutional chromosome 3 translocations. Previously, such co-segregation phenomena have been widely employed to identify candidate genes in various hereditary (cancer) syndromes. Here we survey the translocation 3- positive RCC families that have been reported to date and the subsequent identification of its respective candidate genes using positional cloning strategies. Based on allele segregation, loss of heterozygosity and mutation analyses of the tumors, a multi-step model for familial RCC development has been generated. This model is relevant for (i) understanding familial tumorigenesis and (ii) rational patient management. In addition, a high throughput microarray-based strategy is presented that will enable the rapid identification of novel positional candidate genes via a single step procedure. The functional consequences of the (fusion) genes that have been identified so far, the multi-step model and its consequences for clinical diagnosis, the identification of persons at risk and genetic counseling in RCC families are discussed.
Keywords: chromosome 3 translocations, renal cell cancer, breakpoint cloning, gene identification, multi-step model, genetic counseling
Current Molecular Medicine
Title: Chromosome 3 Translocations and Familial Renal Cell Cancer
Volume: 4 Issue: 8
Author(s): Anita C.M. Bonne, Danielle Bodmer, Eric F.P.M. Schoenmakers, Conny M. van Ravenswaaij, Nicoline Hoogerbrugge and Ad Geurts van Kessel
Affiliation:
Keywords: chromosome 3 translocations, renal cell cancer, breakpoint cloning, gene identification, multi-step model, genetic counseling
Abstract: Renal cell carcinomas (RCCs) occur in both sporadic and familial forms. In a subset of families the occurrence of RCCs co-segregates with the presence of constitutional chromosome 3 translocations. Previously, such co-segregation phenomena have been widely employed to identify candidate genes in various hereditary (cancer) syndromes. Here we survey the translocation 3- positive RCC families that have been reported to date and the subsequent identification of its respective candidate genes using positional cloning strategies. Based on allele segregation, loss of heterozygosity and mutation analyses of the tumors, a multi-step model for familial RCC development has been generated. This model is relevant for (i) understanding familial tumorigenesis and (ii) rational patient management. In addition, a high throughput microarray-based strategy is presented that will enable the rapid identification of novel positional candidate genes via a single step procedure. The functional consequences of the (fusion) genes that have been identified so far, the multi-step model and its consequences for clinical diagnosis, the identification of persons at risk and genetic counseling in RCC families are discussed.
Export Options
About this article
Cite this article as:
Bonne C.M. Anita, Bodmer Danielle, Schoenmakers F.P.M. Eric, Ravenswaaij M. van Conny, Hoogerbrugge Nicoline and Kessel Geurts van Ad, Chromosome 3 Translocations and Familial Renal Cell Cancer, Current Molecular Medicine 2004; 4 (8) . https://dx.doi.org/10.2174/1566524043359593
DOI https://dx.doi.org/10.2174/1566524043359593 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Blockade of Neoangiogenesis, a New and Promising Technique to Control the Growth of Malignant Tumors and their Metastases
Current Vascular Pharmacology NK Cell, Monocyte and Non T Cell Biomarkers as Prognostic Indicators in Cancer Immunotherapy
Current Cancer Therapy Reviews Clinical Significance of miR-1826 as a Novel Prognostic Biomarker in Colorectal Cancer
Anti-Cancer Agents in Medicinal Chemistry Heteroaromatic Pim Kinase Inhibitors Containing a Pyrazole Moiety
Recent Patents on Anti-Cancer Drug Discovery Modulating Co-Stimulation During Antigen Presentation to Enhance Cancer Immunotherapy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Glycoconjugates As Vaccines for Cancer Immunotherapy: Clinical Trials and Future Directions
Anti-Cancer Agents in Medicinal Chemistry Genitourinary Tract Tumors in Children: An Update
Current Pediatric Reviews Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions
Current Medicinal Chemistry Pharmaceutical Inhibition of Neddylation as Promising Treatments for Various Cancers
Current Topics in Medicinal Chemistry Protective and Therapeutic Effects of Ghrelin in the Gut
Current Medicinal Chemistry The Use of Intravenous Aminobisphosphonates for the Treatment of Pagets Disease of Bone
Mini-Reviews in Medicinal Chemistry Insulin-like Growth Factor: Current Concepts and New Developments in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Nitrogen-Containing Bisphosphonates and Cancer Immunotherapy
Current Pharmaceutical Design Potential for Predicting Toxicity and Response of Fluoropyrimidines in Patients
Current Drug Targets Anti-Angiogenic Peptides for Cancer Therapeutics
Current Pharmaceutical Biotechnology Current Status of Thalidomide and CC-5013 in the Treatment of Metastatic Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry Current Concepts in the Diagnosis and Treatment of Type 1 and Type 2 Autoimmune Pancreatitis
Recent Patents on Inflammation & Allergy Drug Discovery Recent Advancements in Pharmacological Stent Therapy Using Polymeric Materials: Opportunities and Challenges
Current Drug Delivery Histamine as a Potential Adjuvant to Immuno and Radiotherapy for Cancer Treatment: Discovering New Functions for the Oldest Biogenic Amine
Current Immunology Reviews (Discontinued) The Heat Shock Protein 90 Chaperone Complex: An Evolving Therapeutic Target
Current Cancer Drug Targets